Table 1 Clinician survey free text responses for ‘other’ option in Figs. 1, 2, 3 and 4

At what point in a patient’s treatment journey do you usually start JAKi therapy? (Fig. 1)

“Only in young patients without comorbidities or risk factors for VTE, and usually when options are limited or a patient is very adverse to injectable therapies.”

- Clinician 9 (Consultant, East of England)

“If perceived advantages for JAKi.”—Clinician 35 (Consultant, Scotland)

If you feel less confident in prescribing a JAKi, compared with other advanced therapies, why is this? (Fig. 2)

“Limited in PsA as upa not yet NICE approved and tofa needs MTX.”—Clinician 23 (Consultant, South East England)

“Cost relative to biosimilars.”—Clinician 35 (Consultant, Scotland)

“New advice for treating at lower levels of DAS28 hasn’t yet been approved in our region.”—Clinician 46 (Consultant, Northern Ireland)

Have you had to discontinue JAKi in your patients? (Fig. 3)

“Safety concerns in people over 65, people with co-morbidities.”—Clinician 9 (Consultant, East of England)

“2 patients developed leg oedema which seemed to be linked [to the JAKi].”—Clinician 26 (Consultant, Greater London)

“Patient planning pregnancy.”—Clinician 35 (Consultant, Scotland)

Has the COVID-19 pandemic affected your prescribing of JAKi? (Fig. 4)

“Not applicable—I did not prescribe JAKi prior to the pandemic as it occurred early in my training”—Clinician 3 (Registrar, East of England)

“Yes—as a short half-life they were seen as being safer than bDMARDs, in respect of SARS-CoV2 (guidance from BSR).”—Clinician 4 (Consultant, East of England)

“Initially I prescribed them for RA patients in preference to rituximab/tocilizumab as didn’t need day unit attendance, and felt safer for older patients as v short half-life. Started to question that when the Covid safety/ vaccine efficacy data came out, and serious doubts set in with the recent safety alerts.”—Clinician 6 (Consultant, East of England)

“Shorter half life.”—Clinician 28 (Consultant, North West England)

“Shorter duration of action so stop if infection.”—Clinician 30 (Consultant, North West England)

“Prescribed more as quick on and quick off so can be discontinued quickly in event of severe infection.”—Clinician 31 (Registrar, Greater London)

“Shorter half life”—Clinician 43 (Registrar, Greater London)